



The human T-cell lymphotropic virus type I (HTLV-I) was 
discovered in 1980. It is the first oncogenic human retrovirus [29]. 
Several diseases have been found to be related to HTLV-I infection, 
as HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/
TSP), adult T-cell leukemia/lymphoma (ATL), polymyositis, uveitis 
and other inflammatory conditions [11, 23, 27, 35, 44].
The most common reasons for HTLV-I transmission are firstly the 
sexual activity, particularly from males to females, through blood 
transfusion of infected cells, and from breast feeding mother to 
child [8, 17, 20, 24, 37]. It is endemic in the Caribbean Islands, 
southwestern Japan, Papua New Guinea, Central Africa and South 
America, including Brazil.
Groups of peoples from various populations were studied in Brazil 
which showed prevalence of different types of HTLV antibodies 
[4, 31]. In several areas HTLV-I prevalence in blood donors ranges 
from 0.4 to 1.8% [9].
The first cases of ATL were reported in Kyoto in 1977, commonly 
occurring in patients from southwestern Japan [41, 44]. The major 
case series explaining the clinical spectrum of ATL comes from 
Japan [38, 46]. Most probably it takes many decades to show, with 
occurrence in 3-5% of infected individuals.
So far, the development of ATL has been mainly linked with early 
HTLV-I infectivity in life, most likely transmission from mother to child 
[43]. ATL presents four distinct clinical subtypes, according to clinical 
features: acute, lymphoma, chronic and smoldering [39]. The clinical 
and laboratory features of ATL include hepatomegaly, enlargement of 
the lymph nodes, splenomegaly, hypercalcaemia and frequent skin 
lesions; morphological appearance in peripheral-blood called “flower” 
cells (convoluted nucleus with polymorphism and multilobulation and 
scanty basophilic cytoplasm) and the presence of HTLV-I antibody. 
The characteristic surface phenotypes of ATL cells are CD4+, CD3+, 
CD25+ and CD8- [32].
The disease has a bad diagnosis owing to an intrinsic resistance of 
leukemic cells to standard or even high doses of chemotherapy in 
addition to a related severe immunosuppressant [2].
The data about the incidence and pathogenesis of ATL in Brazil 
showed the rate of HTLV-I positivity of 28.4% among the patients 
with T-cell disease [4] and ATL has been reported in many parts of 
the country [4, 32].
The objective of the study at hand is to investigate the laboratory and 
clinical features of the patients suffering from T-cell disease HTLV-I, 
suspected of ATL, carried out at HEMORIO, a reference center for 
hematologic diseases in Rio de Janeiro state.
Methods and material
Patients
Starting from January 1995 till December 2007, 46 patients 
with T-cell disease and HTLV-I positive, from HEMORIO electronic 
registry system, were selected and studied retrospectively. Special 
care was taken to record information of epidemiological features, 
sexual lifestyle, co-infection with other virus, and previous blood 
transfusion. The families of the HTLV+ patients were recruited under 
consent and 67 family members were investigated. The criteria for 
ethnic groups considered whites the Brazilians of European descent, 
and nonwhites all blacks and mulattoes, as well as mixed races of 
whites, Amerindian or blacks.
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The finding of  ATL was established on clinical features, hypercalcemia, 
hematological findings, increased LDH value, detection of 
HTLV-I antibodies and immunophenotyping analyses. Four subtypes 
were used to classify the patients according to the classical criteria 
established by Shimoyama et al [39].
Morphology and immunophenotyping
Bone-marrow aspirate and/or peripheral-blood were examined in 
all cases according to Catovsky et al (1984). Immunophenotyping 
analyses were performed routinely using a clean peripheral blood 
mononuclear cell (PBMC) from the patients, by flow cytometry using 
a panel of fluorochrome-conjugated monoclonal antibodies including, 
CD2, CD3, CD4, CD7, CD8, CD25, CD30, CD38, HLADr, CD19 and 
CD45RO, for a four-color fluorescent analysis on a FACS facscalibur 
flow cytometer (BD Biosciences). For patients having leukemic signs, 
the criteria of T-cell type was accepted when above 25% of the 
circulating malignant cells were positive for T-cell markers [5, 32].
HTLV-I serological assays
Collected from the patients, the peripheral blood samples were 
checked for the occurrence of antibodies to HTLV-I and II by the help 
of the enzyme immunoassay (ELISA – Vironostika HTLV-I/II Organon 
Teknika, Boxtel, Holland), in accordance with the manufacturer’s 
directions. Repeatedly reactive on ELISA specimens were further 
given to a Western Blot assay (HTLV BLOT 2.4 Genelabs Diagnostics 
Pte. Ltd., Singapore) for verification and type differentiation in 
accordance with manufacturer ’s guidelines. This examination 
classifies as HTLV-positivity with the sample reactive to, no less than, 
two distinctive HTLV structural gene products: env gD21 and/or 
gp46 and gag p24 and/or p19; viral type was described as HTLV-I or 
HTLV- II when reactive to recombinant gp46-I or gp46-II, respectively; 
as HTLV-indeterminate in case of the pattern not meeting the positivity 
criteria, and as negative in case of total reactivity absence.
HTLV-I molecular assays
Using the ficoll-hypaque density gradient centrifugation, peripheral 
blood mononuclear cells (PBMC) were separated, and extraction 
of DNA was done from PBMC using the QIAamp DNA Blood Mini 
Kit – Qiagen (Hilden Germany), in accordance with manufacturer’s 
guidelines. Finding of HTLV-I sequences was carried out by PCR 
making use of specific primers for three distinguished HTLV genomic 
regions (LTR, tax, pol) as explained elsewhere [7, 36].
Statistical analysis
The 2 test was used to compare race and gender proportion in the 
analyzed group with a p-value of 0.05. Survival rates for each patient 
were calculated from diagnosis confirmation until death or censure.
Data were analyzed with the use of the Kaplan-Meier Curve, and 
Comparisons among ATL subgroups were carried out using log- 
rank test (significance p-value 0.05). Every statistical test was done 
using the Statistical Package for the Social Sciences (SPSS) v.13.0 
software (SPSS Inc, Chicago, II, USA).
Results
Clinical features
Forty-six patients with T-cell disease HTLV-I positive were diagnosed 
between January 1995 and December 2007. ATL was confirmed in 
37 patients enrolled in this study. Among the ATL cases, 22 (59%) 
presented acute subtype, eight (22%) chronic subtype, seven (19%) 
lymphoma type and no cases of smoldering subtype were found. 
During evolution, nineteen of the patients with chronic or lymphoma 
type changed to acute subtype (Tab. I and II).
The main characteristics of the 37 ATL patients are summed up 
in table I, and II. The span of time between the showing of the 
symptoms and the diagnosis varied from eight days to five years 
(just the case 15). Generalized lymphoadenopathy, hepatomegaly, 
splenomegaly, skin lesions and hypercalcaemia were features present 
in many patients (Tab. II). Two of them had osteolytic lesions. There 
were two cases of pulmonary infiltrate (Fig. 1, case 15) and ten cases 
(27%) had central-nervous system involvement. One patient had ATL 
concomitant with Hansen’s disease (Fig. 2, case one). Case eight 
illustrates the typical ATL skin lesion (Fig. 3).
Although HAM/TSP and ATL are distinguished clinical entities caused 
due to HTLV-I, there was one case of ATL concomitantly with HAM/ 
TSP. This patient suffered from sphincter dysfunction, gate difficulty, 
and spastic paraparesis of the lower limbs, brisk reflexes and hyper- 
reflexia with HTLV-I antibodies found in the CSF. Each and every of 
these clinical symptom fulfilled the diagnostic criteria of HAM/TSP 
[18]. These signs began one year before ATL symptoms.
Laboratory features
The results of laboratory findings and risk factors were described in 
table I and II. Eighteen cases (49%) had an increased LDH levels; 
hypercalcaemia was present in 20 patients (54%). The range of 
white-blood-cell (WBC) counts goes from 2,090 to 425,000 k/µl. 
Cell morphology seems to be of nucleus shape and pleomorphic 
in size. Flower cells were found in twenty-three patients (62%) 
peripheral blood. In most cases, the Immunophenotyping by flow 
cytometry was positive for CD2, CD3, CD4, CD5, CD25, HLADr 
and CD45 and negative for CD7, CD8 and CD19, a typical T-cell 
phenotype. Co-expression of positive CD4 and CD8 was found in 
one case and in three patients the CD4 and CD8 were negative. In 
particular CD25 was negative in four cases. All cases had antibodies 
to HTLV-I confirmed by Western Blot; PCR was performed in 22 cases 
and the HTLV-I viral segment was detected in all of them.
Most of the patients (33 out of 37) received CHOP treatment 
(cyclophocphamide, doxorubicin, vincristine and prednisone). Only 
one patient who presented chronic form and two patients who 
presented acute form received CHOP, AZT and Interferon.
Survival analysis
Survival data were compared between the subtypes of ATL using the 
log-rank test and Kaplan-Meier to evaluate statistical significance. 
The period starting from the date of diagnosis till the moment of 
death or censure was defined as the survival time. Cases with 
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missing follow-up or which completed the follow-up period were 
censored alive at that time. Although one of the cases had 
exceeded the following five years (almost 7 years), the data were 
censored on the 60th month of observation.
Analyzing the curves, overall survival data were relatively short 
(median 2.0 months, 95% between 0 and 5.6 months). However, 
those with chronic disease had longer survival (median 15.0 months,
95% between 0 and 37.6 months). The lymphoma subtype group 
had the worst prognosis (median survival 1.0 month). Given the 
small number of cases, it was not possible to detect a statistically 
significant difference between groups (log-rank test 0.74). The 
major reason for death was advancement of the disease linked with 
hypercalcemia and infective complications (Fig. 4). Table describes 
clinical evolution.
Epidemiology
The age of ATL patient was found between 23 to 91 years, with an 
average of 42 years. There were 11 males (30%) and 26 females 
(70%), with significant differences regarding gender in the total group 
analyzed (p = 0.014). Twenty five (67.6%) patients were non-white 
Fig. 1. Case 1: A. Skin lesion in patient with ATL associate to Hansen’s disease. B. Flower cell in peripheral blood. C. Infiltrate by 
lymphocytes in lympho nodes. D. Central-nervous system involvement (blastic cells infiltration). E. CNS infiltration in cerebrospinal 
fluid. F. CT of lumbar with osteolitic lesions in the spine
Fig. 2. Case 10: A and B. Skin infiltration in ATL patient
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Fig. 4. Overall and specific ATL-subtypes survival analysis using KM curves 
and log-rank test
Fig. 3. Case 15: Pulmonary infiltration in ATL. Thorax X-ray in patient with ATL in different occasions. A. In 2000 and B in 2001 (before 























Means and Medians for Survival Time
An Estimation is limited to the largest survival time if it is censored
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Table I. Demographic, ATL subtypes and epidemiological data
CASES Ethnicity
HTLV- I Risk factors
WB PCR HTLV I + Mothers Breast-feeding (time/months) Other risk factors/  epidemiological data
1. 23ys;M;ATL-a NW (+) (+) (+) 6 months None
2. 24ys;M;ATL-1 NW (+) (+) (-) 6 months + wetnurse BD HTLV-I +
3. 25ys;F;ATL-1 W (+) Nd Unknown Unknown Unknown
4. 26ys;M;ATL-1 NW (+) Nd (+) 3 months Sexual promiscuity; addicted
5. 26ys;M;ATL-a W (+) (+) (+) Unknown Unknown
6. 28ys;F;ATL-a W (+) (+) Unknown Unknown Addicted
7. 31ys;F;ATL-a NW (+) (+) (-) 12 months + wetnurse HPV, HBV, sexual promiscuity
8. 34ys;F;ATL-a NW (+) (+) (+) 24 months Addicted
9. 34ys;F;ATL-ca W (+) Nd (+) 3 months None
10. 34ys;F;ATL-a W (+) (+) (+) Unknown BD HTLV-I +, HPV
11. 36ys;M;ATL-1 W (+) (+) (+) 12 months BD HTLV-I +
12. 36ys;F;ATL-a W (+) Nd unknown Unknown Unknown
13. 37ys;F;ATL-a NW (+) (+) (+) Unknown Unknown
14. 39ys;M;ATL-a NW (+) Nd Unknown Unknown Sexual promiscuity; HIV
15. 39ys;F;ATL-ca NW (+) Nd (Deceased) Unknown Anti-Hbc, herpes zoster
16. 39ys;F;ATL-a NW (+) (+) (+) Unknown None
17. 40ys;F;ATL-a NW (+) (+) (-) 24 months + wetnurse None
18. 41ys;F;ATL-a NW (+) (+) (-) 30 months, wetnurse None
19. 42ys;F;ATL-a NW (+) Nd (+) Unknown Mother with HAM/TSP
20. 43ys;F;ATL-a NW (+) Nd (Deceased) 24 months None
21. 43ys;F;ATL-a W (+) Nd Unknown Unknown None
22. 44ys;F;ATL-a NW (+) Nd Unknown Unknown None
23. 45ys;F;ATL-a NW (+) Nd (+) 7 months None
24. 46ys;M;ATL-ca NW (+) Nd Unknown Unknown Mother with myelopathy
25. 46ys;M;ATL-ca NW (+) (+) (+) Unknown Unknown
26. 47ys;F;ATL-1-a NW (+) Nd Unknown Unknown Blood transfusion + HCV
27. 48ys;F;ATL-a NW (+) Nd (+) 7 months BD HTLV-I +
28. 48ys;F;ATL-ca NW (+) (+) Unknown Unknown BD HTLV-I +
29. 49ys;F;ATL-1-a* NW (+) (+) Unknown Unknown Blood transfusion
30. 57ys;F;ATL-a W (+) (+) Unknown Unknown Blood transfusion
31. 57ys;M;ATL-1-a NW (+) (+) Unknown Unknown None
32. 58ys;M;ATL-a W (+) (+) Unknown Unknown none (transferred to)
33. 60ys;F;ATL-a NW (+) (+) Unknown Unknown HCV
34. 70 ys;F;ATL-a W (+) (+) Unknown Unknown Unknown
35. 72ys;M;ATL-c W (+) nd (Deceased) Unknown Blood transfusion
36. 83ys;F;ATL-c NW (+) (+) (Deceased) Unknown Anti-HBc
37. 91ys;F;ATL-ca NW (+) (+) Unknown Unknown None
ATL-a – adult T-cell leukemia/lymphoma acute; ATL-c – adult T-cell leukemia/lymphoma chronic ; ATL-l – adult T-cell leukemia/lymphoma lymphoma
ATL-ca – adult T-cell leukemia/lymphoma chronic evoluted to acute-subtype; ATL-la – adult T-cell leukemia/lymphoma lymphoma evoluted to acute-subtype;
nd = not done; M – Male; F – Female; W – white; NW – non white; BD HTLV-I + – blood donor HTLV-I +; HAM/TSP – HTLV-I-associated myelopathy/tropical spastic paraparesis;
HIV – human immunodeficiency virus; HPV – human papilloma virus; HBV – hepatitis B virus; HCV – hepatitis C virus; * – not smoldering cases were found.
80
Acta Haematologica Polonica
compared to twelve (32.4%) white. There were significant differences 
regarding ethnicity in the total group analyzed (p = 0.033).
According to the regional origin, the patients were from five different 
states of Brazil: thirty were from Rio de Janeiro, four from Bahia, one 
from Pernambuco, one from Maranhão and one from Pará.
Among the entire group, three of the patients were blood donor 
candidates that had positive HTLV-I antibody and were deferred from 
the blood banks. Three of them were drug users (cocaine), three 
others reported sexual promiscuity, and two patients had sexual 
transmissible diseases (STD) being identified as HPV. One of them 
developed uterus carcinoma during the ATL treatment. Four patients 
had been transfused before the ATL diagnosis, twelve patients were 
breast-fed by their mothers, and four patients were breast-fed by wet 
nurses and their mothers were HTLV-I negative. The time of breast- 
feeding varied from three months to two years (Tab. I).
Considering the study of 67 family members of the ATL patients: 
19 mothers, seven spouses, 21 offspring, 20 siblings were analyzed 
for anti-HTLV antibodies. HTLV-I seropositivity was evident in 60% 
of the mothers, 40% of the spouses, 24% of the offspring and 24% 
of the siblings.
Discussion
ATL is a destructive T-cell malignance the primary cause of which 
is HTLV-I infection and it is commonly found in individuals from virus 
endemic regions, for example Brazil. In this country the disease represents 
approximately 28% of the cases of T-cell malignancies [4, 31].
The current study found that among the 46 patients with T-cell 
disease suspected of ATL, only 37 were confirmed as ATL. Although 
some studies in Japan and Jamaica have provided important 
data on pathologic and epidemiological characteristics of ATL, 
in Brazil there are some difficulties in the diagnosis of this disease, 
due to the similarities with other T-lymphoproliferative disorders 
[16, 32, 45]. The clinical features of ATL in Brazil are similar to cases 
from the Caribbean and Japan [16, 32, 46] and among our series of 
ATL patients we found the similar clinical manifestation as reported 
in others Brazilian studies [3, 32]. Co-expression of positive CD4 
and CD8 was found in one case and in three patients the CD4 and 
CD8 were negative. In particular CD25 was negative in four cases. 
These rare immunophenotypic variants were previously reported 
[32]. Hypercalcaemia was present in 54% of the cases, two patients 
presented osteolytic lesions and 37% of the patients presented 
CNS involvement. One patient, besides neurological disease had 
disseminated osteolytic lesions and Hansen’s disease, as previously 
reported [14, 15, 25].
In accordance with the disease presentation form, our results are 
similar to the data reported by Schimoyoma [39] where the frequency 
of ATL subtypes presents acute form 57%, lymphomatosis 19%, 
chronic 19% and smoldering 5%, except in smoldering form, where 
no case was found.
Most of the patients (33 out of 37) received CHOP treatment 
(cyclophocphamide, doxorubicin, vincristine and prednisone). Only 
one patient who presented chronic form and two patients who 
presented acute form received CHOP, AZT and interferon. The 
protocol for ATL in the institution is CHOP, but at the time of the 
research ATL treatment was not available for all patients, which was 
released on July 19th, 2016, according to protocol 58998 of Brazilian 
Health Ministry.
ATL has a bad outcome because of an intrinsic resistance to leukemia 
cells to standard or even elevated doses of chemotherapy, furthermore 
also to a linked severe immunosuppressant. Hence, the probable 
function of typical chemotherapy, a greater dose of chemotherapy, with 
allogenic or autologous bone marrow transplantation is yet to be defined. 
Significant progress was observed with the combination of zidovudine 
(AZT) and interferon-alpha (IFN). As the cure is still not very clear, 
modern therapeutic tactics or new combinations are necessary to be 
Table II. Clinical and laboratory features of ATL patients
Clinical Feature
ATL subtypes Total
Acute (n = 22) Chronic (n = 8 ) Lymphoma (n = 7) 37 (100%)
Lymphadenopathy 11 3 6 20 (54%)
Skin lesions 11 4 2 17 (46%)
Splenomegaly 8 1 1 10 (27%)
Hepatomegaly 13 1 0 14 (38%)
CNS infiltration 7 2 1 10 (27%)
Pulmonary infiltrate 0 2 0 2 (5%)
Osteolytic lesions 2 0 0 2 (5%)
Hypercalcaemia (> 10,3 mg/dl) 15 2 3 20 (54%)
LDH (> 480 u/l) 13 2 3 18 (49%)
WBC > 10 x 10/ml (> 10,2 k/µl) 23 5 3 31 (84%)
Atypical lymphocytes (flower cells) 19 2 2 23 (62%)
CD4 + (> 50%) 15 4 3 22 (59%)
CD25 + (> 15%) 12 4 2 18 (49%)
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Table III. Clinical evolution of ATL patients





1. 23ys;M;ATL-a 5/4/2000 Sim 50 days Organic encephalopathy due to neoplastic 
infiltration + Hypercalcemia metabolic coma + 
pulmonary infection
Sim No
2. 24ys;M;ATL-1 1/30/2002 Sim 16 months Septic Shock Sim No
3. 25ys;F;ATL-1 4/17/2001 Sim 18 days Septic Shock Sim No
4. 26ys;M;ATL-1 Sim Sim No
5. 26ys;M;ATL-a 10/29/2007 Sim 6 months Organic encephalopathy due to neoplastic 
infiltration + pulmonary infection
No
6. 28ys;F;ATL-a 12/4/2006 Sim+AZT+Inter- feron 12 months Alive
7. 31ys;F;ATL-a 6/19/2002 Sim 7 months Septic Shock + accute renal infection Sim No
8. 34ys;F;ATL-a 4/14/2000 Sim 1 months Septic Shock Sim No
9. 34ys;F;ATL-ca 12/21/2001 Sim 41 months Septic Shock Sim No
10. 34ys;F;ATL-a 10/13/2005 Sim 1 months Septic Shock + accute renal infection Sim No
11. 36ys;M;ATL-1 5/29/1995 1 months  
(transferred to)
12. 36ys;F;ATL-a 1/27/2005 Sim 17 months Septic Shock + accute renal infection Sim No
13. 37ys;F;ATL-a 5/26/2007 Sim 6 months Septic Shock Sim No
14. 39ys;M;ATL-a 11/18/1999 Sim 10 days Septic Shock + neoplastic pleural effusion Sim No
15. 39ys;F;ATL-ca 8/28/2001 Sim 29 months Septic Shock Sim No
16. 39ys;F;ATL-a 12/20/1996 Sim 21 months Organic encephalopathy due to neoplastic 
infiltration + pulmonary infection
Sim No
17. 40ys;F;ATL-a 5/18/2001 Não 7 days Organic encephalopathy due to neoplastic 
infiltration + Hypercalcemia metabolic coma + 
Septic Shock
Sim No
18. 41ys;F;ATL-a 5/15/2005 Sim 1 months Septic Shock Sim No
19. 42ys;F;ATL-a 9/1/2006 Sim+AZT+Inter- feron 27 days Septic Shock Sim No
20. 43ys;F;ATL-a 3/22/2001 Sim 81 months Alive
21. 43ys;F;ATL-a 2/10/2005 Sim 2 months Septic Shock Sim No
22. 44ys;F;ATL-a 3/24/2002 Não 1 day Organic encephalopathy due to neoplastic 
infiltration + Septic Shock
Sim No
23. 45ys;F;ATL-a 8/1/2000 Sim 3 months Septic Shock Sim No
24. 46ys;M;ATL-ca 8/17/2005 Sim 28 months Alive
25. 46ys;M;ATL-ca 5/30/2003 Sim 10 months Septic Shock Sim No
26. 47ys;F;ATL-1-a 6/5/2006 Sim 16 months Septic Shock Sim No
27. 48ys;F;ATL-a 4/25/2002 Sim 1 months Septic Shock Sim No
28. 48ys;F;ATL-ca 4/24/2002 Sim 1 months Septic Shock Sim No
29. 49ys;F;ATL-1-a* 1/2/2002 Não 1 day Organic encephalopathy due to neoplastic 
infiltration + Hypercalcemia metabolic coma + 
Septic Shock
Sim No
30. 57ys;F;ATL-a 2/15/2002 Sim 1 months Septic Shock No
31. 57ys;M;ATL-1-a 9/25/2003 Sim 7 days Organic encephalopathy due to neoplastic 
infiltration + accute renal infection
Não No
32. 58ys;M;ATL-a 11/12/1996 Sim 9 months  
(transferred to)
33. 60ys;F;ATL-a 11/25/2003 Sim 2 months Hyperleocostase with leokoestase incentral ner- 
vous system + pulmonary infection
Sim No
34. 70 ys;F;ATL-a 7/5/2007 Não 2 days Organic encephalopathy due to neoplastic 
infiltration + Hypercalcemia metabolic coma + 
Septic Shock
Sim No
35. 72ys;M;ATL-c 5/29/2000 Sim 15 months Hypercalcemia metabolic coma + Septic Shock Sim No
36. 83ys;F;ATL-c 6/15/1992 Sim+AZT+Inter- feron 60 months Septic Shock Sim No
37. 91ys;F;ATL-ca 11/18/2003 Sim 34 months Septic Shock Sim No
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carried out [2]. Different regimes of cytotoxic chemotherapy have been 
employed to cure patients suffering from acute and immunosuppressant 
forms of ATL, however the rates of total response are less than 30% and 
there is a lack of durability in responses [13].
ATL being a major destructive hematological malignancy has a bad 
outcome, either it is acute or lymphoma type, with a survival time 
of 6 to 13 months [47]. According to Lymphoma Study Groups [22], 
the patient’s survival rates were 24.3 month for the chronic type, 
10.2 months for the lymphoma type and 6.2 months for the acute 
form, from a group of 854 individual patients. In a Brazilian study, in 
which 70 ATL cases were analyzed, the overall median survival time 
was 12 months [3]. Yet, we lay serious emphasis on the fact that in 
our study, lymphoma subtype group had the worst prognosis (median 
survival 1.0 month).
ATL commonly occurs in adults, as a minimum of 20-30 years after 
the inception of HTLV-I infection. The persons who have the disease 
transmitted in the childhood time, by vertical transmission, are more 
likely to be at a higher risk of getting the disease [1, 28]. It has been 
reported that the Brazilian patients are younger than the Japanese 
ones. In this study the average age was 42 years old, and it is similar 
to other regions of Brazil and from the Caribbean patients [3, 12, 32]. 
Though mostly ATL is accounted to affect patients in their fifties, in 
Japan [42], in the Jamaican and Brazilian series, the individuals are 
more likely to show the medical symptoms in the forth decade of their 
life [3, 4, 12, 32].
Amongst the HTLV-I-infected carriers the cumulative incidence of ATL, 
is approximated at 1-5% for both males and females in endemic areas 
[26]. In our series, 26 (70%) of the patients were female. Similar results 
were found in a survey conducted in central Brooklyn, which showed 
the yearly incidence of ATL was higher in females as compared 
to males (female-to-male ratio of 3:1) [21], however the disease is 
more common amongst men in Japan. Amongst the HTLV-I carriers in 
Japan, the cumulative incidence of ATL is approximated at 2.5%, with 
1-2% in female and 3-5% in males [46].
In French Guiana, a greater incidence of ATL in blacks has been 
accounted [10] as well as in blacks with mulattos in Pernambuco and 
Bahia States in Brazil [3, 32]. In the present study the disease was 
also majorly found in non-white individuals (68%).
In case of adult HTLV-I infection, the development of ATL is highly 
unusual and merely periodic cases of sexual transmission and/or 
blood transfusion related HTLV-I transmission related with ATL have 
been found [6, 23, 24].
Although in our series four patients have history of blood transfusion 
before the diagnosis, it was not clearly the route of HTLV-I transmission. 
In spite of the fact that HTLV-I infection caused by blood transfusion 
is regarded as a significant danger for HAM/TSP, instances of post- 
transfusion ATL are extraordinary [1, 6, 33]. ATL and HAM/TSP are 
distinguished clinical conditions triggered by HTLV-I, and one or the 
other disease shows up independently in most patients. Although, 
few cases of connection are reported [3, 16, 19, 32]. In our study just 
one patient was found with this disease association.
The incidence of HTLV-I, reported annually, of related disease (ATL) 
has not been found in Brazil [32]. In addition, there are very few 
data available about the path of HTLV-I transmission among family 
settings of individuals with ATL in the region. Carvalho et al. [4] and 
Pombo-de-Oliveira [33], found a HTLV-I seroprevalence rate of 27, 
5% and 36% respectively amongst the family members of individuals 
with ATL and in the present study 35, 8% of the relatives of ATL 
patients analyzed were HTLV-I seropositive.
According to the risk factors, in our study 12 patients were breast-
fed by their mothers and among them 60% were HTLV-I positive 
and wet nurses breast fed four patients and their mothers were 
HTLV-I negative. These are in accordance with data found in 
Caribbean and Japanese cohort studies, where greater than 97% 
of mothers of ATL individuals were as well HTLV-I antibody-positive 
[1, 40].
In conclusion, our data emphasize the importance of the serologic test 
for HTLV-I antibodies, and specific immunophenotyping to differentiate 
ATL from other T-lymphoproliferative disorders. Alternatively, since 
ATL is majorly linked with HTLV-I infection in early years of life, 
transmitted by vertical route, it is very important to include in the 
prenatal routine the HTLV screening test and present the appropriate 
counseling to the seropositive pregnant women regarding to the 
breast-feeding, in order to brake the virus transmission cycle.
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ATL-a = adult T-cell leukemia acute subtype ATL-c = adult T-cell 
leukemia chronic subtype ATL- l = adult T-cell leukemia lymphoma 
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